
    
      In this randomized clinical trial, 40 adults with a principal diagnosis of Adult Separation
      Anxiety Disorder (ASAD) and no major depression or substance abuse disorders will be
      randomized to 12 weeks of treatment with vilazodone (flexibly dosed) or matched pill placebo.
      Outcome will be assessed in respect to symptomatic improvement, quality of life, adverse
      events and safety.
    
  